Tattooing breaches the skin and can, therefore, cause a variety of complications. This book covers the full spectrum of issues clinical practitioners may encounter when treating affected patients. Introductory chapters include educational information on methods for tattooing, types of tattoos, tattoo inks, and tattoo ink toxicology. The focus is on the diagnosis and classification of tattoo complications. In this regard, a comprehensive atlas of acute and chronic complications serves as a valuable tool. Further chapters summarize available therapies, their rationale, and indication. This includes various medical and surgical treatments with a review of dermatome shaving. Lastly, tattoo removal by gold standard YAG lasers and the more recent pico-second lasers is discussed with the optimal therapeutic outcome in mind.

Dermatologists, plastic surgeons, general practitioners, laser surgeons, and other specialists treating tattoo complications will find this book to be an indispensable resource. It also includes information relevant for a broad range of stakeholders in the tattoo business, including authorities and regulators.
Dermatology

An International Journal founded as
“Dermatologische Zeitschrift” by Oskar Lassar (1893–1907)
Continued by Erich Hoffmann (1908–1938), continued as “Dermatologica” (1939–1991),
continued as ‘Dermatology’ since 1992

Editor-in-Chief

Gregor B.E. Jemec – Zealand University Hospital, Roskilde, Denmark

Section Editor “International Dermatology Outcome Measures”

Amit Garg – Hofstra Northwell School of Medicine, Hempstead, USA

Section Editor “Skin Cancer”

Claas Ulrich – Charité – University Medicine Berlin, Berlin, Germany

Section Editor “Tattoo and Body Art”

Jørgen Serup – Bispebjerg University Hospital, Copenhagen, Denmark

Associate Editors

Giuseppe Argenziano – Second University of Naples, Naples, Italy
Perla Calderón – University of Chile, Santiago, Chile
Lars E. French – University Hospital Zurich, Zurich, Switzerland
Robert Gniadecki – Bispebjerg University Hospital, Copenhagen, Denmark
Qiang Ju – Renji Hospital, Shanghai Jiao Tong University, Shanghai, China
Brian Kirby – St. Vincent’s University Hospital, Dublin, Ireland
Dan Lipsker – University of Strasbourg, Strasbourg, France
Branka Marinović – University Hospital Center Zagreb, Zagreb, Croatia
Tetsuo Shiohara – Kyorin University, Tokyo, Japan
H. Peter Soyer – The University of Queensland, Woolloongabba, Australia
Dae Hun Suh – Seoul National University, Seoul, Republic of Korea
Jacek C. Szepietowski – University of Wroclaw, Wroclaw, Poland
Christos C. Zouboulis – Dessau City Clinic, Dessau, Germany

(Continued on next page)
Editorial Board

Tove Agner – Bispebjerg University Hospital, Copenhagen, Denmark
Hervé Bachelez – St. Louis Hospital, Paris, France
Tania Cestari – Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Veronique del Marmol – Université Libre de Bruxelles, Brussels, Belgium
Lennart Emtestam – Karolinska University Hospital and Institutet, Stockholm, Sweden
Alice Gottlieb – Tufts University, Boston, USA
Dimitrios Ioannides – Aristotle University Medical School, Thessaloniki, Greece
Marcel F. Jonkman – University Medical Center Groningen, Groningen, The Netherlands
Sirkku Peltonen – University of Turku and Turku University Hospital, Turku, Finland
Errol P. Prens – Erasmus Medical Center, Rotterdam, Netherlands
Luis Puig – Autonomous University of Barcelona, Barcelona, Spain
Jean Revuz – Private Practice – Dermatology, Paris, France
Eggert Stockfleth – Ruhr University Bochum, Bochum, Germany
Devinder Mohan Thappa – Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
Dermatology

Submission
Only original papers written in English should be sent to:

www.karger.com/drm

S. Karger AG
Prof. Dr. Gregor B.E. Jemec
Editorial Office “Dermatology”
PO Box
CH–4009 Basel (Switzerland)
Tel. +41 61 306 1358
Fax +41 61 306 1434
E-Mail drm@karger.com

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publisher. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Dermatology and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Peer Review Policy
Dermatology is a peer-reviewed journal. Our aim is to provide authors with fast and constructive feedback regarding their submitted manuscript. The Editor-in-Chief and international editorial board ensure a thorough and fair peer review and the highest scientific publishing standards. The Editor-in-Chief is responsible for maintaining a high-quality peer review of papers submitted to the journal.

Types of Papers
The journal accepts the following types of papers:

• Original Papers
• Review Papers
• Industry News
• Basic Science Investigations
• Clinical Investigations
• Novel Treatments
• Surgical Pearls
• Consensus Guidelines

Original Papers: Fully documented reports of original research. They must describe full sets of significant, original experiments in basic science and translational research in dermatology. Consideration for publication is based on originality, novelty, scientific soundness and appropriate analysis. An Abstract, Introduction, Materials and Methods, Results and Discussion sections are required. The abstract should be structured and contain the following parts: Background, Objective, Methods, Results, Conclusion; it should have no more than 250 words. A synopsis of the Material and Methods section must be provided in a flow chart. The detailed paragraph will be published as supplementary material. The submission of raw data as supplementary material is strongly encouraged.

Review Papers: Comprehensive reviews covering a timely topic by experts in the field. Review Papers are usually invited by the Editor but may be unsolicited. An abstract (not structured) of no more than 250 words is required. Review Papers are not subject to page charges, and color illustrations are reproduced free of charge in the printed edition. All published Review Papers are freely accessible online.

Surgical Pearls: Presentation of novel surgical techniques and discussion of their advantages compared to current approaches. Papers of this type should include a short video sequence to be published online.

Consensus Guidelines: Consensus guidelines are welcome from societies or working groups to provide guidance in key and emerging areas in all fields of dermatology.

Sections
International Dermatology Outcome Measures: The section includes papers, the research focus of which is in alignment with the mission of the non-profit organization “International Dermatology Outcome Measures” (IDeOM): The development of evidence-based outcomes measures to evaluate the impact of treatments for patients with dermatological diseases. Please view the above “Types of Papers” list for all different paper categories accepted within this section. All submissions to this section are subject to editorial and peer-review. Dermatology publication conditions apply.

Skin Cancer: The section with a thematic focus on Skin Cancer includes papers on any cancers that arise from the skin (basal-cell cancer (BCC), squamous-cell cancer (SCC) and melanomas). Please view the above “Types of Papers” list for all different paper categories accepted within this section. All submissions to this section are subject to editorial and peer-review. Dermatology publication conditions apply.

Tattoo and Body Art: Dermatology welcomes submissions to the section “Tattoo and Body Art” covering various types of body art and skin modifications (namely tattooing, permanent make-up, body-piercing, scarification, etc.) and including basic research and science on those topics. Please view the above “Types of Papers” list for all paper categories accepted within this section. All submissions to this section are subject to editorial and peer-review. Dermatology publication conditions apply.

Ethics
Published research must comply with the guidelines for human studies and animal welfare regulations. Authors should state that subjects have given their informed consent and that the study protocol has been approved by the institute’s committee on human research. Further, they should also state that animal experiments conform to institutional standards.

Conflicts of Interest
Authors are required to disclose any sponsorship or funding arrangements relating to their research, and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Plagiarism Policy
Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor.

Arrangement
Papers should comprise approximately 13 double-spaced manuscript pages including figures, tables and references. For technical details please refer to:


Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: For indexing purposes, a list of 3–10 key words in English is essential for all papers.

Key message: Kindly provide a sentence of up to 15 words that capture the essence of the content of the paper.

Material and Methods: A synopsis of the Material and Methods section must be provided in a flow chart. The detailed paragraph will be published as supplementary material.

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be stored in separate files. Tables require a heading and figures a legend, also prepared in a separate file. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 600–1200 dpi. For further details, please refer to the Submission Website at www.karger.com/drm.

Color illustrations: All color illustrations will be published in color online and black/white in print. In print, optional publication of illustrations in color is subject to a charge of CHF 960.00 per page.
No charges are imposed for color illustrations of Review Papers.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Avoid using abstracts and posters as references. If necessary, list as footnotes in standard reference format, followed by the designation ‘(abstr.)’ or ‘(poster)’. For posters, add the details of the meeting where presented.

Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication without the need for any modification or editing. Files should not exceed 10 MB in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

Self-Archiving/Green Open Access
Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript after peer review but before production) on their personal or their institution's internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeleavy) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

- Be used for noncommercial purposes only
- Be linked to the final version on www.karger.com
- Include the following statement: "This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytochrome Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/doi/[insert DOI number]."

It is the author's responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)
The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author's Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders' requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants in the Acknowledgements section of their papers.
Pathobiology offers a valuable platform for the publication of high-quality original research into the mechanisms underlying human disease. Aiming to serve as a bridge between basic biomedical research and clinical medicine, the journal welcomes articles from scientific areas such as pathology, oncology, anatomy, virology, internal medicine, surgery, cell and molecular biology, and immunology. Published bimonthly, Pathobiology features original research papers and reviews on translational research. The journal offers the possibility to publish proceedings of meetings dedicated to one particular topic.

Pathobiology
Founded: 1938
Category: Basic and Clinical Research
Field of Interest: Pathology
Listed in bibliographic services, including: PubMed/MEDLINE, Web of Science, Google Scholar, Scopus, Embase
2017: Volume 84
6 issues per volume
Language: English
ISSN 1015–2008
e-ISSN 1423–0291
Impact Factor: 1.732

Selected contributions
- Absence of Microsatellite Instability In Soft Tissue Sarcomas: Campanella, N.C.; Penna, V.; Ribeiro, G.; Abrahão-Machado, L.F.; Scapulatempo-Neto, C. (Barretos); Reis, R.M. (Barretos/Braga/Guimarães)
- Fibroblast Growth Factor Receptor 1 Gene Copy Number and mRNA Expression in Primary Colorectal Cancer and Its Clinicopathologic Correlation: Kwak, Y. (Seoul/Seongnam); Nam, S.K. (Seongnam); Seo, A.N. (Daegu); Kim, D.-W.; Kang, S.-B. (Seongnam); Kim, W.H. (Seoul); Lee, H.S. (Seongnam)
- Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations: Abe, H. (Tokyo); Kaneda, A. (Chiba/Saitama); Fukayama, M. (Tokyo/Saitama)
- Cancer Therapeutic Effects of Titanium Dioxide Nanoparticles Are Associated with Oxidative Stress and Cytokine Induction: Fujiwara, R.; Luo, Y. (Kashiwara); Sasaki, T. (Fukuoka); Fujii, K.; Ohmori, H.; Kuniyasu, H. (Kashiwara)
- Role of the Tumor Microenvironment in Breast Cancer: Soysal, S.D.; Tzankov, A.; Muenst, S.E. (Basel)
- Metabolomics Biomarkers for Breast Cancer: Günther, U.L. (Birmingham)

More information at www.karger.com/pat
Contents

See the journal website for contents
“Great location and organization, excellent talks, very impressed by the number of participants.”
TATJANA PAVICIC, DERMATOLOGIST, GERMANY

“Attended all sessions that I could, and learned an incredible amount of helpful information.”
DIANE DUNCAN, PLASTIC SURGEON, USA

“One of the best conferences I have ever attended, with world class speakers.”
SUSIE RENDRA INTAN, DERMATOLOGIST, INDONESIA

IMCAS Asia is under process of accreditation by SKP IDI, the local organism that grants Continuing Medical Education (CME) credits to Indonesian doctors

MORE INFORMATION AND REGISTER ON IMCAS.COM
Connect with the global dermatological community

Programme highlights

- New trends and innovative treatments in dermatology
- Dermatologic challenges in daily practice
- Paediatric and geriatric skin diseases
- Treatment of infectious diseases around the world
- New approaches in aesthetic dermatology and laser medicine
- Live demonstrations

www.isa2017.com
The 7th 5CC was an exceptional success, with more than 900 attendees from 63 countries and 5 continents, 140 KOLs and more than 250 industry representatives, and we plan to enhance it even further in 2017.

Join us in Barcelona from AUGUST 31 – SEPTEMBER 3, 2017, as we offer you an incredible setting at the stunning Centre de Convencions Internacional de Barcelona (CCIB).

Top 5 Reasons to Attend

1. CME-ACCREDITED AND AFFORDABLE EDUCATION
   - 5CC is accredited by the European Accreditation Council for Continuing Medical Education (EACCME)
   - Delegate fees start as low as € 100

2. UNPARALLELED PLATFORM FOR LEARNING, EDUCATION AND TRAINING
   - Scientific program covers all the many facets of the aesthetic environment
   - Cooperation with over 25 leading international societies and associations in the medical field
   - Pre-Conference Sessions on Home-Use Devices, LED, Aesthetic Gynecology and the latest trends in Dermatologic and Aesthetic Surgery
   - Education on marketing, social media and business optimization
   - Over 300 workshops, symposia, workshops and presentations
   - Promoting the next generation with the 5CC Abstract Award

3. INTENSIVE LEARNING POSSIBILITIES
   - 2-hour, CME-certified Teaching Courses, held by experts in their field
   - Residents & Fellows Day - focusing on the basics for Residents and Fellows in Aesthetic Dermatology

4. PRODUCT DEMONSTRATIONS & DISCUSSIONS
   - Comprehensive industry exhibition on the latest trends & technologies
   - Innovations presented in small-scale industry workshops
   - Product presentations in live-treatments and demonstrations
   - Discussion of trends and technologies in our product roundtables

5. OUTSTANDING VENUE & SIMPLIFIED TRAVEL
   - Barcelona is capital of UNESCO World Heritage Sites
   - Congress venue (CCIB) is the heart of the technology and business district known as Barcelona 22@
   - Over 40 airlines offer direct flights from around the globe to Airport Barcelona-El Prat (BCN)
   - Save up to 20% off your trip to Barcelona with our cooperation with the Star Alliance member airlines
27th German Skin Cancer Congress

21–23 September 2017

MAINZ

Annual meeting of the Dermatologic Cooperative Oncology Group (DeCOG) of the German Cancer Society (DKG) and the German Society of Dermatology (DDG)

Scientific chair
Univ.-Prof. Dr. med. Stephan Grabbe
PD Dr. med. Carmen Loquai

Abstract deadline: 18 May 2017

www.ado-kongress.de
12. DEUTSCHER ALLERGIEKONGRESS
05. – 07. Oktober 2017
Kurhaus Wiesbaden

Kongresspräsidenten
Prof. Dr. Ludger Klimek
Prof. Dr. Wolfgang Wehrmann

www.allergiekongress.de

Online-Anmeldung unter www.allergiekongress.de
Faxanmeldung bitte zurücksenden an:
Fax: +49 611 204 809 - 10

<table>
<thead>
<tr>
<th>Dauerkarte für die Gesamttagung</th>
<th>bis 30.06.2017</th>
<th>ab 01.07.2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitglieder der AeDA</td>
<td>195,00 €</td>
<td>245,00 €</td>
</tr>
<tr>
<td>Mitglieder der DGAKi</td>
<td>245,00 €</td>
<td>295,00 €</td>
</tr>
<tr>
<td>Mitglieder der GPA</td>
<td>195,00 €</td>
<td>195,00 €</td>
</tr>
<tr>
<td>Abtreiberrechtlichen Pfleger, Arztberufe</td>
<td>65,00 €</td>
<td>75,00 €</td>
</tr>
<tr>
<td>Studenten / Doktoranden</td>
<td>50,00 €</td>
<td>50,00 €</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tageskarte für den 06.10.2017</th>
<th>06.10.2017</th>
<th>07.10.2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitglieder der AeDA</td>
<td>105,00 €</td>
<td>125,00 €</td>
</tr>
<tr>
<td>Mitglieder der DGAKi</td>
<td>125,00 €</td>
<td>155,00 €</td>
</tr>
</tbody>
</table>

Rahmenprogramm
- Happy Hour, 05.10.2017
- Gesellschaftsabend, 06.10.2017

AllergoActives
Der Besuch von AllergoActives erfordert eine Voranmeldung. Weitere Informationen und Anmeldung ebenfalls auf: www.allergiekongress.de

Teilnehmerregistrierung
wikonect GmbH
Hagenauer Str. 53 / 65203 Wiesbaden
Tel.: +49 611 204 809 - 22 / info@wikonect.de

Alle Preise verstehen sich pro Person und inkl. 19 % MwSt.
* Nachweis erforderlich (Mitgliedsausweis / Schreiben Arbeitgeber / Arbeitsvertrag / Studienbescheinigung) – bitte an o. g. Faxnummer senden.

Zahlungs- und Stornierungsbedingungen:

Funktionsauswahl
- Kliniker
- Wissenschaftler
- Chefarzt
- Sonstiges

Fachbereich
- Dermatologie
- Pädiatrie
- Arbeits- und Umweltmedizin
- Sonstiges

Newsletter – Allergiekongress
Sie erhalten ausschließlich Informationen zum Kongress und Ihre Daten werden nicht an Dritte weitergegeben.

Einvignung: Ja, ich bin damit einverstanden, aktuelle Informationen über den Allergiekongress per E-Mail-Newsletter zu erhalten.

Hiermit melde ich mich rechtsverbindlich zum Allergiekongress 2017 in Wiesbaden an:

Ort, Datum, Unterschrift, ggf. Stempel
9th World Congress on Itch

October 15-17, 2017
Wroclaw, Poland

ORGANIZERS:
International Forum for the Study of Itch
Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wroclaw, Poland
WCHR 2017
10th World Congress for Hair Research

Kyoto, Japan

Visiting old, find new

Honorary-President Hideoki OGAWA
Co- Presidents Ryoji TSUBOI (SHSR), Satoshi ITAMI (JSCHR)

October 31 (Tue) - November 3 (Fri), 2017
Kyoto International Conference Center

http://www.congre.co.jp/wchr2017/
Towards a personalized approach

The easiest way to order: www.karger.com/drm

Therapeutic Use of Ingenol Mebutate in Dermatology

Editor: Hofbauer, G.F.L. (Zurich)

IV + 32 p., 27 fig., 27 in color, soft cover, 2016
CHF 29.00 / EUR 27.00 / USD 34.00
Soft cover and online prices for personal customers
Prices subject to change, VAT not included
EUR price for eurozone countries,
USD price for USA and Latin America only

Special Topic Issue
Vol. 232, Suppl.1 (2016), Dermatology
Included in subscription

Listed in Journal Citation Reports, PubMed/MEDLINE,
Current Contents, Scopus, Embase

Although ingenol mebutate is registered for the topical treatment of actinic keratoses, it can be used to treat various other conditions. This is because, once applied, the drug directly destroys skin cells and induces inflammation. In this special topic issue of 'Dermatology' select authors share their clinical experience thereby providing a guide to novel uses. Topics include the application of ingenol mebutate with occlusion and a reduced number of applications when treating actinic keratoses. Other cases illustrate the authors' experience with conditions beyond actinic keratosis such as Bowen's disease, warts, basal cell carcinoma, and lentigo maligna.

Dermatologists need to adapt treatments to their patients' individual needs. This case collection serves as an indispensable resource when choosing a suitable approach.

Contents
Preface: Hofbauer, G.F.L.

• Ingenol Mebutate for Recalcitrant Chronic Actinic Cheilitis: Telka, E.; Masouyé, I.; Mühlstädt, M.; Laffitte, E.
• Ingenol Mebutate 500 μg on the Cheekbones with Concomitant Conjunctivitis: Gaide, O.; Cattin, V.
• Ingenol Mebutate 500 μg for Treatment of the Scalp in Refractory Field Cancerization: Gaide, O.; Clayton, H.; Girardin, M.; Kuonen, F.
• Successful Treatment of Relapsing Bowen's Disease with Ingenol Mebutate: The Use of Dermoscopy to Monitor the Therapeutic Response: Mainetti, C.; Guillod, C.; Leoni-Parvex, S.
• Bowenoid Actinic Keratosis and Bowen's Disease Treated Successfully with Ingenol Mebutate: Mohanna, M.T.; Hofbauer, G.F.L.
• Ingenol Mebutate 150 mg as Physician-Directed Treatment of Bowen's Disease Under Occlusion: Alkhalaf, A.; Hofbauer, G.F.L.
• Ingenol Mebutate vs. Daylight Photodynamic Therapy in a Kidney Transplant Recipient: Mühlstädt, M.
• Ingenol Mebutate Treatment in a Patient with Gorlin Syndrome: Stieger, M.; Hunger, R.E.

Author Index/Subject Index

Dear Librarian

I have reviewed this publication and would like to recommend it for our library.

Recommended by:

Department:

Date:

Signature:

Orders may be placed with any bookseller, subscription agency, directly with the publisher or through a Karger distributor.

Karger – Medical and Scientific Publishers
CH–4009 Basel, Switzerland
orders@karger.com, f: +41 61 306 12 34
www.karger.com
704 Unknown Primary Melanoma: Worldwide Survey on Clinical Management
Ribero, S. (Turin); Pampena, R. (Reggio Emilia/Terracina); Bataille, V. (London/Northwood); Moscarella, E. (Reggio Emilia); Thomas, L. (Lyon); Quaglino, P. (Turin); Potenza, C. (Terracina); Van Akkooi, A.C.J. (Amsterdam); Testori, A. (Milan); Nathan, P. (Northwood); Puig, S. (Barcelona/Valencia); Zalaudek, I. (Graz); Argenziano, G. (Naples); Longo, C. (Reggio Emilia/Modena)
The management of unknown primary melanoma is highly heterogeneous; thus, a consensus document is needed.

708 Comparison of “Lesion-by-Lesion” and Field Photodynamic Therapy in the Prevention of Actinic Keratoses: A Randomized, Split-Face, Single-Blind Pilot Study
Seubring, I.; Groenewoud, J.M.M.; Gerritsen, M.-J.P. (Nijmegen)
In-patient comparison of “lesion-by-lesion” and “field” MAL-PDT (methyl aminolevulinate photodynamic therapy) demonstrates the superiority of field MAL-PDT with respect to the prevention of actinic keratoses.

715 What Is the Key to Improving Renal Transplant Recipients' Awareness of Skin Cancer Risk?
Borghi, A.; Corazza, M.; Battaglia, Y.; Maietti, E.; Minghetti, S.; Virgili, A. (Ferrara)
Improving the way education is delivered to transplant recipients may increase their awareness of skin cancer risk.

721 Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients
Dereure, O.; Missan, H.; Girard, C.; Costes, V.; Guillot, B. (Montpellier)
Cetuximab alone or with chemotherapy may control locally advanced or metastatic cutaneous squamous cell carcinoma.

731 Risk Factors for Skin Infections in Mycosis Fungoides
Lebas, E.; Arrese, J.E.; Nikkels, A.F. (Liège)
Late-stage mycosis fungoides patients with extended lesions should be closely monitored for cutaneous (viral, bacterial, or fungal) infections.

738 Characterization of Cutaneous Plasmacytosis at Different Disease Stages
Hsiao, P.-E.; Wu, Y.-H. (Taipei/New Taipei)
This study characterizes the features of cutaneous plasmacytosis at different stages of the disease.

748 Luminex LiquiChip System for the Evaluation of Cytokine Levels in Patients with Contact Dermatitis to Potassium Dichromate
Akerman, L.; Klein, T.; Israeli, M.; Fraser, A. (Petah Tikva/Tel Aviv); Sagy, E.; Snait, I. (Petah Tikva); Mimouni, D.; David, M.; Trattner, A. (Petah Tikva/Tel Aviv)
The Luminex LiquiChip is a promising in vitro method for the diagnosis of allergic contact dermatitis.

752 Clinical Presentation of Cutaneous Leishmaniasis caused by Leishmania major
Remadi, L. (Monastir); Haouas, N. (Monastir/Hail); Chaara, D.; Slama, D.; Chargui, N. (Monastir); Dabghi, R.; Jbeniani, H. (Kairouan); Mezhoud, H.; Babba, H. (Monastir)
This article presents an overview of the clinical polymorphism of cutaneous leishmaniasis caused by Leishmania major in Tunisia.

760 Acknowledgement to Referees

Original Paper

762 Contents Vol. 232, 2016
Psoriasis and Obesity

Jensen, P.; Skov, L. (Hellerup)

Psoriasis is associated with obesity, and therefore nutritional care should be part of the management of psoriasis.

Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT

Maul, J.-T.; Djamei, V.; Kolios, A.G.A.; Meier, B. (Zurich); Czernielewski, J. (Lausanne); Jungo, P. (Basel); Yawalkar, N. (Bern); Mainetti, C. (Bellinzona); Laffitte, E. (Geneva); Spehr, C. (Hamburg); Anliker, M. (St. Gallen); Streit, M. (Aarau); Augustin, M.; Rustenbach, S. (Hamburg); Conrad, C. (Lausanne); Hafner, J. (Zurich); Boehncke, W.-H. (Geneva); Borradori, L. (Bern); Gilliet, M. (Lausanne); Itin, P. (Basel); French, L.E. (Zurich); Häusermann, P. (Basel); Navarini, A.A. (Zurich)

Current therapeutic targets of PASI75 were reached in only 58% in this real-world setting.

Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients

Talamonti, M.; Galluzzo, M.; Servoli, S.; D'Adamio, S.; Bianchi, L. (Rome)

The assessment of alexithymia should be a part of the comprehensive care of psoriasis patients.

Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry

Jungo, P. (Basel); Maul, J.-T.; Djamei, V. (Zurich); von Felten, S. (Basel); Kolios, A.G.A. (Zurich); Czernielewski, J. (Lausanne); Yawalkar, N. (Bern); Odermatt, O. (St. Gallen); Laffitte, E. (Geneva); Anliker, M. (St. Gallen); Streit, M. (Aarau); Augustin, M. (Hamburg); Conrad, C. (Basel); Hafner, J. (Zurich); Boehncke, W.-H. (Geneva); Gilliet, M. (Lausanne); Itin, P. (Basel); French, L.E.; Navarini, A.A. (Zurich); Häusermann, P. (Basel)

Biologics improve the subjective disease activity more than conventional systemic drugs as shown in a Swiss real-life psoriasis registry.

Impaired Pulmonary Function in Patients with Psoriasis


Psoriasis patients demonstrate impaired pulmonary function compared with control subjects.